ACCOUNTS - Final Accounts preparation

Registered number: 09970031

Curadev Pharma Limited

Financial statements

Information for filing with the registrar

For the year ended 31 March 2025

Curadev Pharma Limited

Registered number: 09970031

Balance sheet

As at 31 March 2025

		2025		2024
Note		£		£

Fixed assets
Tangible assets	4		199		299
			199		299
Current assets
Debtors: amounts falling due within one year	5	9,651		68,067
Cash at bank and in hand		101,182		214,769
		110,833		282,836
Creditors: amounts falling due within one year	6	(55,170)		(53,805)
Net current assets			55,663		229,031
Total assets less current liabilities			55,862		229,330

Net assets			55,862		229,330

Capital and reserves
Called up share capital	7	200,500	200,500
Profit and loss account		(144,638)	28,830
		55,862	229,330

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 2 December 2025.

Manish Tandon	Arjun Surya
Director	Director

The notes on pages 2 to 8 form part of these financial statements.

Page 1

Curadev Pharma Limited

Notes to the financial statements

For the year ended 31 March 2025

1.	General information

Curadev Pharma Limited is a private company limited by shares and is incorporated in England with registration number 09970031. The registered office address of the company is 2nd Floor 168 Shoreditch High Street, London, E1 6RA.

2.Accounting policies

2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The financial statements have been rounded to the nearest pound.

The following principal accounting policies have been applied:

The following principal accounting policies have been applied:

2.2

Going concern

The company's forecasts and projections, taking account of expected expenditure and future investment and income, show the company should be able to continue its activities within the level of its available resources and facilities for the foreseeable future. In order to meet its day to day working capital requirements the company will continue to rely upon support provided by its Parent company as and when the need arises. In addition, Mr Manish Tandon (a director of this company and group shareholder) has provided confirmed that he would also provide support to the Curadev Pharma Limited if required.

Consequently the going concern basis has been adopted in preparing these financial statements.

Page 2

Curadev Pharma Limited

Notes to the financial statements

For the year ended 31 March 2025

2.Accounting policies (continued)

2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

2.4

Operating leases: the Company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

2.5

Research and development

Research and development costs are recognised as an expense in profit or loss when incurred.

2.6

Interest income

Interest income is recognised in profit or loss using the effective interest method.

2.7

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 3

Curadev Pharma Limited

Notes to the financial statements

For the year ended 31 March 2025

2.Accounting policies (continued)

2.8

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:

∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and

∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

2.9

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment

20%

Straight Line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.10

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 4

Curadev Pharma Limited

Notes to the financial statements

For the year ended 31 March 2025

2.Accounting policies (continued)

2.11

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.12

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.13

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Page 5

Curadev Pharma Limited

Notes to the financial statements

For the year ended 31 March 2025

2.Accounting policies (continued)

2.13

Financial instruments (continued)

Basic financial assets

Basic financial assets, which include trade and other debtors, cash and bank balances, are initially measured at their transaction price (adjusted for transaction costs except in the initial measurement of financial assets that are subsequently measured at fair value through profit and loss) and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other debtors due with the operating cycle fall into this category of financial instruments.

Impairment of financial assets

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

Financial assets are impaired when events, subsequent to their initial recognition, indicate the estimated future cash flows derived from the financial asset(s) have been adversely impacted. The impairment loss will be the difference between the current carrying amount and the present value of the future cash flows at the asset(s) original effective interest rate.

If there is a favourable change in relation to the events surrounding the impairment loss then the impairment can be reviewed for possible reversal. The reversal will not cause the current carrying amount to exceed the original carrying amount had the impairment not been recognised. The impairment reversal is recognised in the profit or loss.

Basic financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other creditors, bank loans and other loans are initially measured at their transaction price (adjusting for transaction costs except in the initial measurement of financial liabilities that are subsequently measured at fair value through profit and loss). When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future payments discounted at a market rate of interest, discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade creditors are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.

Page 6

Curadev Pharma Limited

Notes to the financial statements

For the year ended 31 March 2025

Employees

The average monthly number of employees, including directors, during the year was 3 (2024 - 3).

4.	Tangible fixed assets

		Office equipment
		£
	Cost or valuation
	At 1 April 2024	499
	At 31 March 2025	499
	Depreciation
	At 1 April 2024	200
	Charge for the year on owned assets	100
	At 31 March 2025	300
	Net book value
	At 31 March 2025	199
	At 31 March 2024	299

Debtors

					2025	2024
					£	£


Other debtors	6,529	61,474
Prepayments and accrued income	3,122	6,593
	9,651	68,067

6.	Creditors: Amounts falling due within one year
		2025	2024
		£	£

Trade creditors	30,020	16,153
Other taxation and social security	-	2,495
Other creditors	-	257
Accruals and deferred income	25,150	34,900
	55,170	53,805

Page 7

Curadev Pharma Limited

Notes to the financial statements

For the year ended 31 March 2025

7.	Share capital
		2025	2024
		£	£

Allotted, called up and fully paid

2,005,000 (2024 - 2,005,000) Ordinary shares of £0.10 each	200,500	200,500

8.	Related party transactions
	All related party transactions during the current year and prior periods, including key management personnel compensation, were made under normal market conditions.

9.	Controlling party

The ultimate controlling party is considered to be Curadev Pharma Pvt. Ltd, India, by virtue of their majority shareholding. Thier registered office address is H-3/63, First Floor, Vikaspuris, New Delhi-110018, India.

10.	Auditors' information

The auditors' report on the financial statements for the year ended 31 March 2025 was unqualified.

The audit report was signed on 3 December 2025 by Mark Attwood FCCA (Senior statutory auditor) on behalf of Kreston Reeves Audit LLP.

Page 8